Telehealth & Digital Health

Rapid health checks are transforming cardiovascular care in London, as a new initiative expands to 70 pharmacies, shifting services from hospitals to the high street.

A new partnership embeds at-home diagnostics into Innovaccer's AI platform, aiming to revolutionize how health plans close care gaps and manage risk.

The FDA has expanded clearance for iotaMotion's robotic-assisted system, offering a new level of surgical precision for children with profound hearing loss.

A new partnership reveals how integrating mental health is revolutionizing oncology, improving patient outcomes, and setting a new standard for whole-person care.

One of the nation's largest health systems is expanding its use of advanced AI and analytics to redefine clinical excellence and whole-person care.

As Disc Medicine nears a potential drug launch, its new HR chief hire reveals a critical strategy for navigating biotech's intense talent wars.

With new federal guidelines backing whole foods, programs delivering 'prescription produce' are proving they can cut healthcare costs and fight chronic disease.

New 2025 data reveals an AI platform is slashing costs, improving chronic disease outcomes, and closing health equity gaps for hundreds of clinicians.

Biomea Fusion launches a high-stakes 2026 plan, advancing a novel diabetes drug to restore insulin cells and an oral pill to rival obesity giants.

With its new thalassemia drug AQVESME launching, Agios aims for blockbuster status while navigating a key safety warning and advancing a broad pipeline.

Teladoc Health's enhanced service integrates specialist consults and data analytics, moving beyond urgent care to reshape healthcare costs and patient outcomes.

As its single-dose glaucoma therapy nears trials, Diorasis adds a seasoned dealmaker to its board, signaling a strategic shift toward market entry.

A new alliance aims to advance KFRX06, a unique Parkinson's therapy that goes beyond a single target to potentially offer a more comprehensive treatment.

After resolving manufacturing hurdles, Camurus' self-administered acromegaly treatment Oclaiz is back on track for US approval, promising new hope for patients.

With promising data in hard-to-treat cancers, iOnctura's lead drug, roginolisib, is set to make waves at the top healthcare investment forum.

With a key FDA decision looming, Orca Bio's massive new funding aims to commercialize a therapy that could make curative transplants safer for more patients.

With a key drug in late-stage trials and a bolstered team, Palvella Therapeutics aims to deliver the first FDA-approved therapies for rare skin diseases.

Riding a 50% revenue surge, Rhythm Pharmaceuticals faces a pivotal year with a major FDA decision and key clinical data for its rare obesity treatments.

With $82M in funding and novel gene insertion technology, Averna Therapeutics is poised to make waves at the pivotal J.P. Morgan Healthcare Conference.

Savara's potential new therapy for autoimmune PAP, MOLBREEVI, gets a powerful partner in PANTHERx Rare, promising a new era of comprehensive patient care.